GSK, RSV and Shingles
GSK's RSV, Shingles vaccines show on-par immune response in joint trial
British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot together generated the same immune response in a late-stage trial as separate adminstration of the vaccines.
GSK Sees Positive Results in Trial of Combination RSV, Shingles Vaccine
GSK recorded positive topline data in a late stage trial of its respiratory syncytial virus vaccine combined with a shingles vaccine in treating adults 50 years and older. The British pharma giant said Wednesday a Phase 3 study evaluating RSV vaccine Arexvy co-administered with Shingrix met the primary endpoint,
The GSK share price has had a rotten few years and now it's heading south yet again. Investor Harvey Jones continues to hang ...
Congress in Spain were a major feature of research news last week, including those from Pfizer on it ponsegromab in cancer ...
ESMO: GSK's Zejula misses survival goal in first-line ovarian cancer, as pharma&'s combo disappoints
In a rough day for PARP inhibitors in ovarian cancer, GSK’s Zejula didn’t deliver a life extension benefit in the final ...
Depemokimab was shown to reduce exacerbations in patients with severe asthma. The proportions of adverse events of ...
Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is upon us ...
With the expiration of a contract to produce antibiotic medicines for Sandoz, GSK will shutter a 75-year-old manufacturing ...
GSK’s long-acting asthma treatment has been shown to halve the number of attacks in a pair of phase 3 trials, supporting the ...
GSK announced on Wednesday that it has reached confidential settlements in two lawsuits filed in California State Court ...
DeepWell Digital Therapeutics received 510 (k) clearance from the FDA on its biofeedback software development kit for use in ...
After announcing a phase 3 launch based on positive midstage results, iTeos and GSK are finally sharing the highlights from ...
GlobalData on MSN4d
MHLW accepts GSK’s multiple myeloma treatment NDA for reviewJapan's MHLW has accepted for review GSK's NDA for Blenrep for patients with relapsed or refractory multiple myeloma.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback